March 10, 2026

BioHealth Innovation, Inc. (BHI) is pleased to announce the appointment of Dr. Nilay Shah to its Board of Directors. A physician–executive with more than 20 years of experience in global clinical development and commercial strategy, Dr. Shah brings deep expertise in advancing innovative therapies from early development through regulatory approval and market entry.

Dr. Shah currently serves as Senior Vice President and Global Head of Ophthalmology at Emmes, where he leads the company’s fastest-growing therapeutic division and serves on the Executive Management Committee. Over the course of his tenure, he has helped scale the organization into a global CRO serving biotech innovators across North America, Europe, Latin America, and Asia. His experience spans Phase I through Phase III trials, FDA and EMA engagement, pharmacovigilance, and strategic alliances with emerging and growth-stage life sciences companies.

The Montgomery County Government and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) officially launched the HJF Innovation Labs at Montgomery County. This new facility at the company’s offices in Bethesda is designed as a regional biotech incubator tailored for startups and small companies developing dual-use (military and civilian) medical technologies.

"This brings much needed small biotech lab space to North Bethesda and strengthens our growing life sciences ecosystem," said Montgomery County Executive Marc Elrich. "Our partnership with HJF is mutually beneficial—raising the County’s innovation capacity while expanding our profile as a center for new technologies. County entrepreneurs can work on dual use technologies in collaboration with HJF, use their space here, and connect to global resources, including clinical trial sites around the world."

The Montgomery County Economic Development Corporation (MCEDC) said in a press release that the facility responds to the demand for smaller-scale lab space with shared equipment, wraparound services, and better access to meaningful innovation support and community resources.

During a June 2025 trade mission to the United Kingdom and France, Virginia Economic Development Partnership leaders and then-Gov. Glenn Youngkin met with AstraZeneca officials. Thirty-three days later, on July 21, the U.K.-based drugmaker announced it would invest $50 billion in the U.S. by 2030, with “the cornerstone” of the investment being a weight management and metabolic products manufacturing facility in Virginia.

A speedy site selection process occurred in those 33 days, including a meeting where VEDP presented site options and workforce solutions to AstraZeneca leadership, followed by a second company visit to Virginia that was “kind of a whirlwind day, where they visited several of the sites that we had presented,” VEDP President and CEO Jason El Koubi says. “And ultimately, it was through that visit that they identified a particular site.”

The Montgomery County Chamber of Commerce will host its Life Science Forum on March 24, bringing together leaders from across the region’s biotechnology, research, and healthcare sectors. The event offers a focused look at the trends shaping the life sciences industry and the role Montgomery County plays in advancing innovation and economic growth.

Attendees will hear insights from industry experts and regional leaders while connecting with professionals across the life sciences ecosystem. The forum is designed for business and community leaders who want a clearer view of the sector’s direction, workforce needs, and opportunities for collaboration within one of the nation’s leading biotech hubs.

On March 19th, the Montgomery County Economic Development Corporation (MCEDC) is bringing together a distinguished panel of business and investment leaders to share their insights on growth, risk, and opportunity in Montgomery County.

Access to capital remains one of the most critical drivers of business growth and long-term sustainability. As market conditions evolve, local businesses must navigate shifting investor expectations, financing strategies, and economic uncertainty while identifying new opportunities for expansion.

On March 19, join our panel of key Montgomery County leaders and investors to discuss how...

The BioHealth Capital Region continues to grow as one of the nation’s leading biohealth clusters, driven by research excellence, capital access, federal partnerships, and a deep bench of experienced operators. Each year, BioHealth Capital Region Week brings that momentum together under one roof.

The 12th Annual BioHealth Capital Region Week will take place September 15th through 17th, 2026, once again hosted at the US Pharmacopeia in Rockville, Maryland. Over three days, leaders from industry, government, academia, and the investment community will convene to address the opportunities and challenges shaping the future of biohealth.

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), has awarded funding to research teams through its Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. GLIDE will give healthcare providers a powerful new toolkit of therapies that directly target abnormal lymphatic structure and function. GLIDE is the first major effort to directly address the root causes of chronic diseases due to underlying lymphatic disease, not just the symptoms. 



The human body is made up various systems that...

BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility, REPROCELL now offers a comprehensive, end-to-end workflow for clinical iPSC manufacturing. This integrated service spans from StemRNA™ clinical seed iPSC manufacturing and StemEdit gene editing to GMP Master Cell Bank (MCB) production in compliance with FDA standards. By unifying these critical steps, REPROCELL enables cell therapy developers to...

Quantum Biotechnology: Bridging the Gap from Innovation to Impact

The goal of the workshop is to highlight the current state of the art in quantum sensing, quantum reporters, quantum control, and quantum analysis of complex, large scale biological data and to identify opportunities in technology development. To bridge the gap from innovation to impact, the workshop will also determine the needs of the biomedical community for improved sensing, reporting, control, and analysis capabilities.

Wednesday April 8 2026- Friday April 10, 2026 - location: The Hotel - College Park, Maryland 

Advisory Board: David Awschalom, Valentina Benfenati, Krastan Blagoev, Warwick Bowen, Gretchen Campbell, Lincoln Carr, John T. Fourkas, Don Lamb, Arnold Levine, Peter Littlewood, Wolfgang Losert, Peter Maurer, Prineha Narang, José Onuchic, Birol Ozturk, Ronald L Walsworth, Nicole Yunger Halpern 

Central Virginia’s biosciences industry is growing faster than other areas across the state and the nation and the region must act now to prepare its workforce for a wave of advanced manufacturing and life sciences expansion.

Today, CvilleBioHub released Talent Pathways: A Biosciences Workforce and Talent Strategy for GO Virginia Region 9, a comprehensive workforce roadmap developed in partnership with TEConomy Partners and funded by GO Virginia.



The Talent Pathways initiative was made possible through the partnership and leadership of GO Virginia Region 9, with critical support from Albemarle County Economic Development and the City of Charlottesville Economic Development.